Other reports have also described Apo2L ligand‐agonist antibody co‐targeting and bispecific antibody‐based approaches to increase anti‐tumor DR5 signaling (Graves et al, 2014; Shivange et al, 2018; Wajant, 2019). The gene discussed is TNFRSF10B; the disease is neoplasm.